Neuraxpharm and Panaxia have taken the next step forward in their partnership on medical cannabis, with the first export of sublingual tablets from Israel to France as part of a pilot program organized by local regulator ANSM.
Neuraxpharm And Panaxia Take Cannabis Tablets To France
Comes Shortly After Panaxia Malta Facility Granted EU GMP Status
Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.
More from Strategy
• By
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.